ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,406.70
0.57%
S&P ASX All Technology
3,915.30
0.60%
Brent Oil
72.355
-0.13%
US Dollar vs AUD
1.54443
-0.01%
Bitcoin
93,142.55
1.27%
Pepperstone
Advertisement
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Legend Biotech Corporation (LEGN)

  7. Legend Biotech Corporation (LEGN) News

LEGN

Legend Biotech (LEGN)

Legend Biotech Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LEGN
DateTimeSourceHeadlineSymbolCompany
15/11/202400:46Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LEGNLegend Biotech Corporation
12/11/202423:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
12/11/202423:00GlobeNewswire Inc.Legend Biotech Reports Third Quarter 2024 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
07/11/202423:30GlobeNewswire Inc.Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and ExpositionNASDAQ:LEGNLegend Biotech Corporation
06/11/202401:10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
06/11/202401:10GlobeNewswire Inc.Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
04/11/202423:30GlobeNewswire Inc.Legend Biotech Appoints Alan Bash as President of CARVYKTI®NASDAQ:LEGNLegend Biotech Corporation
24/10/202423:00GlobeNewswire Inc.Legend Biotech to Host Investor Conference Call on Third Quarter 2024 ResultsNASDAQ:LEGNLegend Biotech Corporation
22/10/202423:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
22/10/202407:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
15/10/202422:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
03/10/202421:30GlobeNewswire Inc.Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in PhiladelphiaNASDAQ:LEGNLegend Biotech Corporation
28/09/202406:35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
28/09/202406:35GlobeNewswire Inc.CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second LineNASDAQ:LEGNLegend Biotech Corporation
26/09/202405:30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
21/09/202406:43Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
21/09/202400:46Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
20/09/202422:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
27/08/202421:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
20/08/202422:00GlobeNewswire Inc.Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:LEGNLegend Biotech Corporation
09/08/202421:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
09/08/202421:00GlobeNewswire Inc.Legend Biotech Reports Second Quarter 2024 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
09/08/202419:50IH Market NewsUS Futures Climb Following Thursday’s Rally, Oil Prices SteadyNASDAQ:LEGNLegend Biotech Corporation
09/08/202406:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
09/08/202406:05GlobeNewswire Inc.Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of DirectorsNASDAQ:LEGNLegend Biotech Corporation
26/07/202421:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
26/07/202421:00GlobeNewswire Inc.Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024NASDAQ:LEGNLegend Biotech Corporation
17/07/202421:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
10/07/202422:00GlobeNewswire Inc.Legend Biotech to Host Investor Conference Call on Second Quarter 2024 ResultsNASDAQ:LEGNLegend Biotech Corporation
02/07/202422:00GlobeNewswire Inc.Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
 Showing the most relevant articles for your search:NASDAQ:LEGN

Your Recent History

BIT
P1QRL8
BNP Paribas Issuance
BIT
P1P2W4
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for ASX Level 1 & 2

1 year 40%, 2 years 40% and *3 years 60%

*Across 3 years $1958.40 only $783.36